Related Experiment Video
Updated: May 16, 2026

Monitoring Dynamic Growth of Retinal Vessels in Oxygen-Induced Retinopathy Mouse Model
Published on: April 2, 2021
Insulin-like growth factor binding protein-3 in preterm infants with retinopathy of prematurity
Manizheh Mostafa Gharehbaghi1, Ali Peirovifar, Karim Sadeghi
1Women's Reproductive Health Research Center, Department of Pediatrics and Neonatology, Tabriz University of Medical Sciences, Tabriz, Iran.
Insights
Lower levels of insulin-like growth factor binding protein -3 (IGFBP-3) are linked to retinopathy of prematurity (ROP) in premature infants. This suggests IGFBP-3 deficiency may play a role in the development of ROP.
Area of Science:
- Neonatology
- Ophthalmology
- Endocrinology
Background:
- Retinopathy of prematurity (ROP) is a leading cause of vision loss in premature infants.
- Understanding the pathogenesis of ROP is crucial for developing effective interventions.
Purpose of the Study:
- To investigate the association between insulin-like growth factor binding protein -3 (IGFBP-3) and proliferative ROP.
- To explore the potential role of IGFBP-3 in the disease's development in premature infants.
Main Methods:
- A case-control study involving 71 preterm infants (≤32 weeks gestation).
- 41 infants without ROP (control group) and 30 with severe ROP (case group).
- Blood samples analyzed for IGFBP-3 levels using ELISA 6-8 weeks after birth.
Main Results:
- Infants with proliferative ROP had significantly lower IGFBP-3 blood levels compared to controls (P=0.009).
- Lower Apgar scores were observed in the ROP group.
- Plasma IGFBP-3 levels showed 65.9% sensitivity and 66.7% specificity for vasoproliferative ROP.
Conclusions:
- Significantly lower IGFBP-3 blood levels were found in premature infants with ROP.
- IGFBP-3 deficiency is suspected to contribute to the pathogenesis of proliferative ROP.
Background:
Retinopathy of prematurity (ROP) is the main cause of visual impairment in preterm newborn infants.
Objective:
This study was conducted to determine whether insulin-like growth factor binding protein -3 (IGFBP-3) is associated with proliferative ROP and has a role in pathogenesis of the disease in premature infants.
Materials And Methods:
A total of 71 preterm infants born at or before 32 weeks of gestation participated in this study. Studied patients consisted of 41 neonates without vaso-proliferative findings of ROP as the control group and 30 preterm infants with evidence of severe ROP in follow up eye examination as the case group. Blood samples obtained from these infants 6-8 weeks after birth and blood levels of IGFBP-3 were measured using enzyme-linked immunosorbent assay (ELISA).
Results:
The mean gestation age and birth weight of the studied patients were 28.2 ± 1.6 weeks and 1120.7 ± 197 gram in the case group and 28.4 ± 1.6 weeks and 1189.4 ± 454 gram in the control group (P=0.25 and P=0.44 respectively). The infants in the case group had significantly lower Apgar score at first and 5 min after birth. Insulin-like growth factor binding protein -3 (IGFBP-3) was significantly lower in the patients with proliferative ROP than the patients without ROP [592.5 ± 472.9 vs. 995.5 ± 422.2 ng/ml (P=0.009)]. Using a cut-off point 770.45 ng/ml for the plasma IGFBP-3, we obtained a sensitivity of 65.9% and a specificity of 66.7% in the preterm infants with vasoproliferative ROP.
Conclusion:
Our data demonstrated that the blood levels IGFBP-3 was significantly lower in the patients with ROP and it is suspected that IGFBP-3 deficiency in the premature infants may have a pathogenetic role in proliferative ROP.
Related Concept Videos
Diabetic Retinopathy
Type I Diabetes III: Clinical Manifestations
Diabetes Mellitus: Type 2 and Gestational

